Brief: Inflarx Announces Decision To Enter Phase 3 Development Of Ifx-1 In Severe Covid-19 Induced Pneumonia
21/07/2020 12:44
July 21 (Reuters) - Inflarx NV IF0G.DE :
* INFLARX ANNOUNCES DECISION TO ENTER PHASE III DEVELOPMENT
OF
IFX-1 IN SEVERE COVID-19 INDUCED PNEUMONIA
* INFLARX NV - TO INITIATE DOUBLE-BLINDED, RANDOMIZED,
PLACEBO-CONTROLLED PHASE III TRIAL THAT WILL BE ADEQUATELY
POWERED FOR STATISTICAL ANALYSES
Source text for Eikon: ID:nGNXbbVwlM
Further company coverage: IF0G.DE
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Inflarx NV
See all newsBrief: Inflarx NV Files For Offerng Of Ordinary Shares, Size Not Disclosed - SEC Filing
Brief: InflaRx Reports Full Year 2025 Results And Highlights Key Achievements And Expected Milestones
Brief: Inflarx Announces Late-Breaker Oral Presentation On Vilobelimab Phase 3 Results In Pyoderma Gangrenosum At 2026 American Academy Of Dermatology Annual Meeting
Brief: Inflarx NV Executing 30% Workforce Reduction
Brief: Inflarx Provides Update On Phase 3 Data Analyses For Vilobelimab In Pyoderma Gangrenosum